Phospho-EGFR Antibody (pTyr1173) / EGFR Activation and Signaling Marker [clone RM269] (R20286)

Description

Epidermal growth factor receptor (EGFR), also known as ERBB1 or HER1, is a transmembrane receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation through ligand-dependent activation. Phospho-EGFR Antibody (pTyr1173) is designed to specifically detect EGFR phosphorylated at tyrosine 1173, a key residue associated with receptor activation and downstream signaling. This site is one of the major autophosphorylation positions that mediates recruitment of adaptor proteins and propagation of intracellular signaling cascades. This Phos-EGFR antibody is part of our phosphorylated target antibody selection.

Upon binding of ligands such as epidermal growth factor (EGF), EGFR undergoes dimerization and autophosphorylation of multiple intracellular tyrosine residues, including Tyr1173. Phosphorylation at this site creates a docking platform for signaling molecules that initiate pathways such as MAPK, PI3K-AKT, and STAT signaling. Detection of phosphorylation at Tyr1173 therefore serves as a direct indicator of EGFR activation status rather than total receptor expression.

In contrast to total EGFR antibodies, phospho-specific antibodies provide insight into dynamic signaling events and receptor activation in response to extracellular stimuli. EGFR phosphorylation is tightly regulated and often transient, making it a valuable readout for ligand stimulation, pathway inhibition, and therapeutic response. Increased phosphorylation at Tyr1173 is commonly observed following EGF treatment and can be reduced by EGFR-targeted inhibitors, highlighting its importance in signaling studies.

EGFR activation plays a critical role in cancer biology, where dysregulated signaling contributes to tumor growth, survival, and resistance to therapy. Aberrant phosphorylation of EGFR is frequently observed in tumors with receptor overexpression or activating mutations. Monitoring phospho-EGFR levels allows researchers to assess pathway activation and evaluate the effectiveness of targeted treatments in both in vitro and in vivo systems.

Phospho-EGFR (Tyr1173) is typically detected in the cytoplasmic region of the receptor following activation, often accompanied by receptor internalization and trafficking to endosomal compartments. This dynamic localization reflects active signaling processes and receptor turnover. The use of a phospho-EGFR antibody enables precise analysis of receptor activation, making it a powerful tool for studies of signal transduction, drug response, and cancer progression.

Explore our EGFR Antibody (31G7) page for a broader view of EGFR expression and extensively validated antibody performance across applications.

Application Notes

The stated application concentrations are suggested starting points. Titration of the Phospho-EGFR Antibody (pTyr1173) / EGFR Activation and Signaling Marker may be required due to differences in protocols and secondary/substrate sensitivity.

1. A pH6 Citrate buffer or pH9 Tris/EDTA buffer HIER step is recommended for testing of FFPE tissue sections.

Immunogen

A phospho-peptide corresponding to human phospho- EGFR (Tyr1173) was used as the immunogen for this recombinant Phospho-EGFR antibody.

Storage

Store the Phospho-EGFR antibody at -20oC (with glycerol) or aliquot and store at -20oC (without glycerol).

Alternate Names

Phospho-EGFR antibody, EGFR pTyr1173 antibody, EGFR Tyr1173 antibody, Phosphorylated EGFR antibody, ERBB1 phospho antibody, clone RM269 antibody